MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.92
Index: ASX200 | ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.26

30 Oct
2026

-0.060

OPEN

$2.26

-2.59%

HIGH

$2.30

3,452,259

LOW

$2.20

TARGET
$4.20

-0.20 change from previous day

 85.8% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) - 1.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-6.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx177.5 M
Book Value Per Share xxxxxxxxxxxxxxx63.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-98.8 M
Net Profit Margin xxxxxxxxxxxxxxx-47.82 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-9.80 %
Return on Invested Capital xxxxxxxxxxxxxxx-8.46 %
Return on Assets xxxxxxxxxxxxxxx-7.34 %
Return on Equity xxxxxxxxxxxxxxx-9.80 %
Return on Total Capital xxxxxxxxxxxxxxx-7.17 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-100.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx164 M
Total Debt xxxxxxxxxxxxxxx184 M
Goodwill - Gross xxxxxxxxxxxxxxx194 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx149 M
Price To Book Value xxxxxxxxxxxxxxx3.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx0.75 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx225 M
Research & Development xxxxxxxxxxxxxxx144 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/11/2026

1

Buy

$4.20

85.84%

Mesoblast reported cash receipts in the September quarter increased by 40% to US$35m while operating expenses were relatively stable.

The clinical program is ongoing. Bell Potter estimates between 50 and 60 hospitals are now on board for the use of Ryoncil and many are yet to complete a first patient treatment.

The broker lowered forecasts for revenue in FY27 by -18%, to now be largely in line with consensus at US$161m. Target is reduced to $4.20 from $4.40 and the Buy rating is retained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.72 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 14.35 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

02/11/2026

1

Buy

$3.52

55.75%

Canaccord Genuity maintains a Buy rating for Mesoblast with its target price unchanged at $3.52 following insights from a key opinion leader call regarding Ryoncil's paediatric growth potential and broader market opportunities.

The discussion reinforced confidence in clinical progress, upcoming adult Phase III trials, and the potential to accelerate commercialisation.

Canaccord Genuity notes that the company's absence of insurer rejections provides support for broader market adoption.
Access Extra Coverage Research History >

MSB STOCK CHART

FNArena News on MSB

1
Australian Broker Call *Extra* Edition – Nov 02, 2026

Nov 02 2026 - Daily Market Reports
2
Rudi’s View: Post-August Stock Picks & Best Buys

Sep 10 2026 - Rudi's View
3
Rudi’s View: Resources, Healthcare & Best Buys

Sep 03 2026 - Rudi's View
4
Australian Broker Call *Extra* Edition – Aug 31, 2026

Aug 31 2026 - Daily Market Reports
5
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
2
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
3
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
4
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
6
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
7
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
8
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
9
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
10
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals